Bridged Bicyclo Compounds, Heterocyclic
"Bridged Bicyclo Compounds, Heterocyclic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heterocyclic compounds that contain two rings that share two non-adjacent atoms in common.
| Descriptor ID |
D019086
|
| MeSH Number(s) |
D03.605.084
|
| Concept/Terms |
Bridged Bicyclo Compounds, Heterocyclic- Bridged Bicyclo Compounds, Heterocyclic
- Bicyclo Compounds, Heterocyclic
- Heterocyclic Bicyclo Compounds
- Bicyclic Heterocyclic Compounds
- Heterocyclic Compounds, Bicyclic
- Heterocyclic Cpds, Bicyclic
- Bicyclic Heterocyclic Cpds
|
Below are MeSH descriptors whose meaning is more general than "Bridged Bicyclo Compounds, Heterocyclic".
Below are MeSH descriptors whose meaning is more specific than "Bridged Bicyclo Compounds, Heterocyclic".
This graph shows the total number of publications written about "Bridged Bicyclo Compounds, Heterocyclic" by people in this website by year, and whether "Bridged Bicyclo Compounds, Heterocyclic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 5 | 5 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
| 2024 | 2 | 2 | 4 |
| 2025 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bridged Bicyclo Compounds, Heterocyclic" by people in Profiles.
-
Dinaciclib improves treatment response in chemoresistant hepatoblastoma. Sci Rep. 2025 Dec 05; 16(1):1410.
-
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML. Blood. 2025 Nov 20; 146(21):2608-2611.
-
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenstr?m macroglobulinemia. Blood Adv. 2025 Oct 14; 9(19):4842-4847.
-
Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenstr?m macroglobulinaemia. Br J Haematol. 2025 Jun; 206(6):1604-1614.
-
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D. JCO Precis Oncol. 2024 Sep; 8:e2400258.
-
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol. 2024 Apr; 11(4):e276-e286.
-
Comprehensive characterization of IFN? signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat Commun. 2024 Feb 28; 15(1):1821.
-
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-na?ve Waldenstr?m macroglobulinemia. Blood. 2024 02 15; 143(7):582-591.
-
Venetoclax in Previously Treated Waldenstr?m Macroglobulinemia. J Clin Oncol. 2022 01 01; 40(1):63-71.
-
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. Leukemia. 2021 09; 35(9):2621-2634.